Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desloratadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desloratadine SCHEMBL29390260 | 1.00 | HRH1 (1.00) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL4425 | 1.00 | HRH1 (1.00) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5200429 | 0.99 | HRH1 (0.97) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5200118 | 0.99 | HRH1 (0.97) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL4574215 | 0.99 | HRH1 (0.97) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5198706 | 0.99 | HRH1 (0.97) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5374223 | 0.97 | HRH1 (0.95) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL5378852 | 0.97 | HRH1 (0.95) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL3558046 | 0.94 | HRH1 (0.89) | HRH1MEN1LMNAADRB2CHRM2 | |
| Desloratadine SCHEMBL28307951 | 0.94 | HRH1 (0.89) | HRH1MEN1LMNAADRB2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144745-A1 | Sugar Free Soft Chew Tablets | FERTIN PHARMA A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| US-20260144746-A1 | Protein Based Soft Chew Tablets | FERTIN PHARMA A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4707391-A1 | NUCLEIC ACID COMPOUNDS FOR ZPI INHIBITION | e-therapeutics PLC (GB) | 2026-03-11 | — | — | EP | disclosed |
| US-12551439-B2 | Flowpack for oral delivery of active ingredients | FERTIN PHARMA A/S (DK) | 2026-02-17 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250325483-A1 | FLOWPACK WITH COMPOSITION FOR IMPROVED TASTE MASKING OF ACTIVES | FERTIN PHARMA AS (DK) | 2025-10-23 | — | — | US | disclosed |
| US-20250177308-A1 | Oral Powder Mixture With Small Sized Particles | FERTIN PHARMA A/S (DK) | 2025-06-05 | — | — | US | disclosed |
| WO-2025108529-A1 | SOFT CHEW TABLETS SUITABLE FOR ANTACIDS | FERTIN PHARMA A/S (DK) | 2025-05-30 | — | — | WO | disclosed |
| CN-115515563-A | Compression molded packaging for oral delivery of active ingredients | 费尔廷制药公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-109963553-B | Oral delivery vehicle | 费尔廷制药公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4088716-A1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | Fertin Pharma A/S (DK) | 2022-11-16 | — | — | EP | disclosed |
| US-11484503-B2 | Tablet comprising separate binder and erythritol | FERTIN PHARMA A/S (DK) | 2022-11-01 | — | — | US | disclosed |
| CN-109952092-B | Tablet comprising separate binder and erythritol | 费尔廷制药公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-3773511-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2022-07-06 | — | — | EP | disclosed |
| US-11351162-B2 | Oral delivery vehicle containing flavoring agents | FERTIN PHARMA A/S (DK) | 2022-06-07 | — | — | US | disclosed |
| US-20220151586-A1 | ULTRASOUND BLOOD-FLOW MONITORING | CIMON MEDICAL AS (NO) | 2022-05-19 | — | — | US | disclosed |
| US-11260030-B2 | Oral tablet for delivery of active ingredients to the gastrointestinal tract | FERTIN PHARMA A/S (DK) | 2022-03-01 | — | — | US | disclosed |
| WO-2022025168-A1 | CONTROL OF ACTIVATION OF MAST CELLS AND BASOPHILS VIA COAGULATION/FIBRINOLYSIS SYSTEM AND COMPLEMENT, AND PHARMACEUTICAL USE THEREOF | 国立大学法人広島大学 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144745-A1 | Sugar Free Soft Chew Tablets | SI, TREH, SLC2A3 | HRH1 313/4885MEN1 3784/4885LMNA 1338/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | HRH1 559/4885MEN1 3283/4885LMNA 1753/4885 |
| US-12551439-B2 | Flowpack for oral delivery of active ingredients | GCK, SLC2A8, SLC2A1 | HRH1 1989/4885MEN1 4288/4885LMNA 3581/4885 |
| US-20260144746-A1 | Protein Based Soft Chew Tablets | CARHSP1, HIRA, HEATR6 | HRH1 278/4885MEN1 4307/4885LMNA 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.